Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Journal:

Hepatology

Published:

2026-05-07

DOI:

10.1097/hep.0000000000001781

Affiliations:

34

Authors:

58

Go to article

Institutions	Authors	Share
Nippon Medical School, Japan	4.000000	0.07
Kobe University, Japan	4.000000	0.07
Ehime University, Japan	4.000000	0.07
Kagawa Prefectural Central Hospital, Japan	3.000000	0.05
Hyogo Medical University, Japan	3.000000	0.05
Kansai Medical University (KMU), Japan	3.000000	0.05
Ehime Prefectural Central Hospital, Japan	3.000000	0.05
Himeji Red Cross Hospital, Japan	2.000000	0.03
Kagawa University, Japan	2.000000	0.03
National Hospital Organization Takasaki General Medical Center, Japan	2.000000	0.03
Okayama City Hospital, Japan	2.000000	0.03
Ogaki Municipal Hospital, Japan	2.000000	0.03
Teine Keijinkai Hospital, Japan	2.000000	0.03
Kindai University, Japan	2.000000	0.03
Wakayama Rosai Hospital, Japan	2.000000	0.03
Hamamatsu University School of Medicine, Japan	2.000000	0.03
Gunmaken Saiseikaimaebashi Hospital, Japan	2.000000	0.03
Saiseikai Niigata Hospital, Japan	1.500000	0.03
Kobe Asahi Hospital, Japan	1.000000	0.02
Hyogo Prefectural Harima-Himeji General Medical Center, Japan	1.000000	0.02
Takamatsu Red Cross Hospital, Japan	1.000000	0.02
Kakogawa City Hospital, Japan	1.000000	0.02
Osaka Medical and Pharmaceutical University, Japan	1.000000	0.02
Asahi General Hospital, Japan	1.000000	0.02
Matsuyama Red Cross Hospital, Japan	1.000000	0.02
Iwate Medical University, Japan	1.000000	0.02
University Hospital, University of Toyama, Japan	1.000000	0.02
Hanwa Memorial Hospital, Japan	1.000000	0.02
Takarazuka City Hospital, Japan	1.000000	0.02
Gifu Kyoritsu University, Japan	0.500000	0.01
Hiroshima University (HU), Japan	0.500000	0.01
Niigata Cancer Center Hospital, Japan	0.500000	0.01

Interested in Oncology and Carcinogenesis?